Table 4.
Prevalence of Suspected LS and LS in different studies
| Authors, year |
Population
(N) |
MMR-deficient (suspected LS)
N (%) |
MMR-deficient (suspected LS) in EEC
˨
N (%) |
Most prevalent MMR-deficient |
LS in
MMR-deficient N (%) |
LS in EC
˨
(%) |
LS in EEC
N (%) |
|---|---|---|---|---|---|---|---|
| Arab M et al, 2021 | 100 | 23 (23) | 22 (24.17) | ||||
| Ismael, 2020 (17) | 60 | 28 (45) | All loss, PMS2 | ||||
| Dondi, 2020 (5) | 239 | 96 (40) | MLH1, PMS2 | 18 (18.75) | 7.5 | ||
| Gordhandas, 2020 (18) | 7057 | 1612 (23) | MLH1 | 212/900 (24) |
3 | ||
| Saeki, 2019 (19) | 98 | 23 (23.5) | |||||
| Reijnen*, 2019 (7) | 128 | 57 (44.5) | |||||
| Chao, 2019 (20) | 111 | 26 (23.5) | MLH1/PMS2 | 6 (23%) | 5.4 | 6/87(6.89) | |
| Kahn, 2019 (21) | 5917 | 1672 (28) | MSH2 | 206(12.3%) | 3 | ||
| Backes*, 2019 (8) | 197 | 64 (32.48) | 64 (32.48) | ||||
| Kim, 2018 (22) | 173˨ | 45 (26) | 45 (26) | MLH1/PMS2 | |||
| Cosgrove, 2017 (23) | 466 | 116 (24.9) | MLH1/PMS2 | ||||
| Mass-Moya. 2016 (16) | 215 | 72 (33) | 11/52 (21.15) | ||||
| Mills, 2016 (10) | 210 | 66 (31.4) | MLH1, PMS2 | 7/55 (26.2) | 3.33 | ||
| Buchanan, 2014 (24) | 702 | 170 (24) | MLH1/PMS2 | 22 (13) | 3 | 21/572 (3.7) | |
| Ferguson, 2014 (25) | 118 | 34 (29) | MLH1, PMS2 | 7 (20.58) | 5.9 | ||
| Peterson, 2012 (26) | 98 | 23 (24) | MLH1/PMS2 | ||||
| Total | 15087 | 4104 (27.20) | 131/461 (28.4) | 489/3005 (16.27) | 489/14354 (3.40) |
27/659 (4.11) |
EC: Endometrial cancer, EEC: Endometrioid endometrial cancer *In Backes and Reijnen studies, high risk population were included